Stifel Nicolaus Forecasts Strong Price Appreciation for GH Research (NASDAQ:GHRS) Stock

GH Research (NASDAQ:GHRS) had its price objective upped by Stifel Nicolaus from $18.00 to $32.00 in a research note published on Thursday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of GH Research in a research report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Monday, January 27th. Finally, Canaccord Genuity Group decreased their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, GH Research has an average rating of “Buy” and an average price target of $30.60.

GH Research Price Performance

GHRS opened at $10.65 on Thursday. The business has a 50 day moving average price of $10.44 and a two-hundred day moving average price of $9.20. The company has a market capitalization of $554.10 million, a price-to-earnings ratio of -13.48 and a beta of 0.93. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.06. Equities analysts expect that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new position in shares of GH Research in the fourth quarter worth approximately $44,000. Two Sigma Investments LP acquired a new position in GH Research in the 4th quarter worth approximately $117,000. Millennium Management LLC purchased a new position in GH Research during the 4th quarter worth approximately $145,000. AdvisorShares Investments LLC raised its stake in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after purchasing an additional 4,806 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of GH Research by 26.8% in the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).